Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 re-treatment study of ALXN2220 in transthyretin amyloid cardiomyopathy
NL-OMON59890Phase 2Active, not recruiting
- Sponsor
- Neurimmune
- Start
- Sep 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cliramitug in amyloidotic transthyretin cardiomyopathy (ATTR-CM), sponsored by Neurimmune. Primary endpoints: Change from baseline to Visit 16 in cardiac magnetic resonance imaging and Change from baseline to Visit 16 in scintigraphy. Started Sep 2025; status: active, not recruiting.
02
Drugs
cliramitug
03
Conditions
amyloidotic transthyretin cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on NL-OMON59890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59890.